Drugs Made In America Acquisition Corp
DMAAU10.490USD
+0.010+0.10%
交易中 （美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Drugs Made In America Acquisition Corp 公司
Drugs Made In America Acquisition Corp. 是一家空白支票公司。該公司成立爲豁免公司，旨在與一家或多家企業進行合併、股份交換、資產收購、股份購買、資本重組、重組或其他類似的業務合併。該公司尋找潛在目標企業的努力不會侷限於特定行業或地理區域，儘管該公司打算專注於尋找製藥行業的業務合併目標。
Drugs Made In America Acquisition Corp簡介
公司代碼DMAAU
公司名稱Drugs Made In America Acquisition Corp
上市日期Jan 28, 2025
CEOMs. Lynn Stockwell
員工數量- -
證券類型Unit
年結日- -
公司地址1 East Broward Boulevard
城市FT LAUDERDALE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編33301
電話19548703099
網址
公司代碼DMAAU
上市日期Jan 28, 2025
CEOMs. Lynn Stockwell
Drugs Made In America Acquisition Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn C. Worman
Mr. Glenn C. Worman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn C. Worman
Mr. Glenn C. Worman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Drugs Made In America Acquisition LLC
17.88%
RiverNorth Capital Management LLC
1.79%
Context Capital Management LLC
1.07%
Wolverine Asset Management, LLC
0.55%
Bulldog Investors, LLP
0.24%
其他
78.46%
持股股東
持股股東
佔比
Drugs Made In America Acquisition LLC
17.88%
RiverNorth Capital Management LLC
1.79%
Context Capital Management LLC
1.07%
Wolverine Asset Management, LLC
0.55%
Bulldog Investors, LLP
0.24%
其他
78.46%
股東類型
持股股東
佔比
Corporation
17.88%
Investment Advisor/Hedge Fund
2.25%
Hedge Fund
1.68%
Research Firm
0.20%
Investment Advisor
0.08%
其他
77.91%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
19
986.13K
4.21%
-2.44M
2025Q2
20
7.49M
31.98%
+6.93M
2025Q1
20
7.60M
32.43%
+7.41M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Drugs Made In America Acquisition LLC
4.19M
17.88%
+4.19M
--
Feb 18, 2025
RiverNorth Capital Management LLC
420.50K
1.79%
--
--
Jun 30, 2025
Context Capital Management LLC
250.00K
1.07%
--
--
Jun 30, 2025
Wolverine Asset Management, LLC
130.00K
0.55%
--
--
Jun 30, 2025
Bulldog Investors, LLP
57.30K
0.24%
-72.96K
-56.01%
Jun 30, 2025
Clear Street LLC
45.92K
0.2%
+40.07K
+685.09%
Jun 30, 2025
Robinson Capital Management, LLC
30.00K
0.13%
+20.00K
+200.00%
Jun 30, 2025
Tuttle Capital Management, LLC
20.00K
0.09%
-20.00K
-50.00%
Jun 30, 2025
UBS Financial Services, Inc.
18.39K
0.08%
+107.00
+0.59%
Jun 30, 2025
Citadel Advisors LLC
14.03K
0.06%
-1.73K
-10.96%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
SPAC and New Issue ETF
2.51%
RiverNorth Enhanced Pre-Merger SPAC ETF
0.49%
CrossingBridge Pre-Merger SPAC ETF
0%
SPAC and New Issue ETF
佔比2.51%
RiverNorth Enhanced Pre-Merger SPAC ETF
佔比0.49%
CrossingBridge Pre-Merger SPAC ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
